Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report

Nicola Montano, Maurizio Martini, Liverana Lauretti, Alessandro Olivi, Luigi Maria Larocca, Roberto Pallini, Quintino Giorgio D'Alessandris, Tonia Cenci, Fabrizio Pignotti, Eduardo Marcos Fernandez Marquez

Risultato della ricerca: Contributo in rivistaArticolo in rivista

2 Citazioni (Scopus)

Abstract

Treatment options for recurrent glioblastoma are scarce; targeted therapy trials were disappointing, probably due to enrollment of patients without molecular selection. We treated with bevacizumab and erlotinib a 66-year-old male suffering from recurrent glioblastoma, IDH-wildtype and MGMT unmethylated, after three neurosurgeries. Treatment was tailored on molecular profile of recurrent tumor-namely, EGFRvIII positivity, VEGF overexpression, normal PTEN, low total VEGF and VEGF-121 mRNA-and resulted in complete, exceptionally durable response (51-month progression-free survival). Notably, histology of further recurrence after therapy was reminiscent of sarcoma. We suggest a thorough molecular screening for personalization of targeted therapy in recurrent glioblastoma
Lingua originaleEnglish
pagine (da-a)2387-2391
Numero di pagine5
RivistaActa Neurochirurgica
DOI
Stato di pubblicazionePubblicato - 2018

Keywords

  • targeted therapy

Fingerprint

Entra nei temi di ricerca di 'Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report'. Insieme formano una fingerprint unica.

Cita questo